OJVM  Vol.2 No.2 , June 2012
Evaluation of Mast Cells in Dermal versus Subcutaneous Hemangiomas and Hemangiosarcomas in Dogs
Abstract: This study investigated the role of mast cells in canine cutaneous vascular tumors, and is the first such study to distinguish between tumors arising in the dermis versus the subcutis. Mast cell numbers in canine cutaneous hemangiomas (HA) and hemangiosarcomas (HSA) were evaluated to identify a relationship between mast cells, tumor type (HA, HSA), histologic location (dermis, subcutis) and tumor recurrence. One hundred and sixty-seven biopsies from 148 dogs were evaluated. Using only one biopsy from each dog, mast cell counts (MCC) for each tumor (n = 148) were obtained by averaging the number of mast cells counted in ten 400× fields. A significant difference in mean MCC was found only between tumor types, with HA having more mast cells than HSA (4.2 ± 4.2 vs. 2.2 ± 2.6; p < 0.001). No significant difference in mean MCC existed between tumors that recurred and those that did not. There was no difference in recurrence rate between tumor type or histologic location. Our results indicate that benign HA contain more mast cells than malignant endothelial cell tumors, regardless of histologic location; whether this is a cause or effect relationship remains to be determined.
Cite this paper: K. Barber, K. Newkirk, A. Reed and R. Donnell, "Evaluation of Mast Cells in Dermal versus Subcutaneous Hemangiomas and Hemangiosarcomas in Dogs," Open Journal of Veterinary Medicine, Vol. 2 No. 2, 2012, pp. 60-65. doi: 10.4236/ojvm.2012.22010.

[1]   M. A. Scott and S. L. Stockham, “Basophils and Mast Cells,” In: B. V. Fedlman, O. W. Schalm, J. G. Zinkl and N. C. Jain, Eds., Schalm’s Veterinary Hematology, 5th Edition, Lippincott Williams & Wilkins, Baltimore, 2000, pp. 308-317.

[2]   K. Norrby, “Mast Cells and Angiogenesis,” Acta Pathologica Microbiologica et Immunologica Scandinavica, Vol. 110, No. 5, 2002, pp. 355-371. doi:10.1034/j.1600-0463.2002.100501.x

[3]   S. Mukaratirwa, L. Chikafa, R. Dliwayo and N. Moyo, “Mast Cells and Angiogenesis in Canine Melanomas: Malignancy and Clinicopathological Factors,” Veterinary Dermatology, Vol. 17, No. 2, 2006, pp. 141-146. doi:10.1111/j.1365-3164.2006.00505.x

[4]   L. M. Duncan, L. A. Richards and M. C. Mihn Jr., “Increased Mast Cell Density in Invasive Melanoma,” Journal of Cutaneous Pathology, Vol. 25, No. 1, 1998, pp. 11-15. doi:10.1111/j.1600-0560.1998.tb01683.x

[5]   S.-Y. Tan, Y. Fan, H.-S. Luo and Z.-X. Shen, “Prognostic Significance of Cell Infiltrations of Immunosurveillance in Colorectal Cancer,” World Journal of Gastroenterology, Vol. 11, No. 8, 2005, pp. 1210-1214. doi:10.1177/104063870401600606

[6]   P. Schultheiss, “A Retrospective Study of Visceral and Nonvisceral Hemangiosarcoma and Hemangiomas in Domestic Animals,” Journal of Veterinary Diagnostic Investigation, Vol. 16, No. 6, 2004, pp. 522-526.

[7]   T. L. Gross, P. J. Ihrke, E. J. Walder and V. K. Affolter, “Skin Diseases of the Dog and Cat: Clinical and Histopathologic Diagnosis,” 2nd Edition, Blackwell Science, Oxford, 2006.

[8]   M. H. Goldschmidt and M. J. Hendrick, “Tumors of the Skin and Soft Tissues,” In: D. J. Meuren, Ed., Tumors in Domestic Animals, 4th Edition, Iowa State University Press, Ames, 2002, pp. 45-117.

[9]   A. M. Hargis, P. J. Ihrke, W. L. Spangler and A. A. Stannard, “A Retrospective Clinicopathologic Study of 212 Dogs with Cutaneous Hemangiomas and Hemangiosarcomas,” Veterinary Pathology, Vol. 29, No. 4, 1992, pp. 316-328. doi:10.1177/030098589202900406

[10]   M. Woldemeskel and S. Rajeev, “Mast Cells in Canine Cutaneous Hemangioma, Hemangiosarcoma and Mammary Tumors,” Veterinary Research Communications, Vol. 34, No. 2, 2010, pp. 153-160. doi:10.1007/s11259-010-9341-1

[11]   S. Sabattini and G. Bettini, “An Immunohistochemical Analysis of Canine Haemangioma and Haemangiosarcoma,” Journal of Comparative Pathology, Vol. 140, No. 2-3, 2009, pp. 158-168. doi:10.1016/j.jcpa.2008.10.006

[12]   A. K. Abbas and A. H. Lichtman, “Cellular and Molecular Immunology,” 5th Edition, Elsevier Science, Philadelphia, 2003.

[13]   K. Yonemaru, H. Sakai, M. Murakami, T. Yanai and T. Masegi, “Expression of Vascular Endothelial Growth Factor, Basic Fibroblast Growth Factor, and Their Receptors (Flt-1, Flk-1, and Flg-1) in Canine Vascular Tumors,” Veterinary Pathology, Vol. 43, No. 6, 2006, pp. 971-980. doi:10.1354/vp.43-6-971

[14]   M. A. Grimbaldeston, J. J. Finlay-Jones and P. H. Hart, “Mast Cells in Photodamaged Skin: What Is Their Role in Skin Cancer?” Photochemical and Photobiological Sciences, Vol. 5, No. 2, 2006, pp. 177-183. doi:10.1039/b504344a

[15]   H. Ward, L. E. Fox, M. B. Calderwood-Mays, A. S. Hammer and C. G. Couto, “Cutaneous Hemangiosarcoma in 25 Dogs: A Retrospective Study,” Journal of Veterinary Internal Medicine, Vol. 8, No. 5, 1994, pp. 345-348. doi:10.1111/j.1939-1676.1994.tb03248.x

[16]   K.-B. Shiu, A. B. Flory, C. L. Anderson, J. Wypij, C. Saba, H. Wilson, I. Kurzman and R. Chun, “Predictors of Outcome in Dogs with Subcutaneous or Intramuscular Hemangiosarcoma,” Journal of the American Veterinary Medical Association, Vol. 238, No. 4, 2011, pp. 472-479. doi:10.2460/javma.238.4.472